# Imatinib Mesylate in Treating Patients With Metastatic Melanoma

> **NCT00027586** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Melanoma
- Skin Neoplasms

## Interventions

- **DRUG:** Imatinib mesylate (STI571)

## Key facts

- **NCT ID:** NCT00027586
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2005-01
- **Final completion:** 2005-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00027586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00027586, "Imatinib Mesylate in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00027586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*